

LION BIOSCIENCE AG
Form 6-K
March 31, 2004

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

**Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934**

LION BIOSCIENCE AKTIENGESELLSCHAFT

(Exact Name of Registrant as Specified in its Charter)

FEDERAL REPUBLIC OF GERMANY

(Jurisdiction of Incorporation or Organization)

Waldhofer Str. 98

D-69123 Heidelberg

Germany

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Edgar Filing: LION BIOSCIENCE AG - Form 6-K

Form 20-F Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If Yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not Applicable

Edgar Filing: LION BIOSCIENCE AG - Form 6-K

A Translation of LION bioscience Aktiengesellschaft's notice to the Federal Supervisory Agency for Financial Services (Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin)) is attached as Exhibit 99.1 and incorporated by reference in this Form 6-K.

Any statements contained in this documents that are not historical facts are forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Words such as anticipate, target, believe, estimate, expect, forecast, intend, may, plan, project, and will and similar expressions as they related to the Company are intended to identify such forward-looking statements. The Company undertakes no obligations to publicly update or revise any forward-looking statements. All forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially from expectations. The factors that could affect the Company's future financial results are discussed more fully in the Company's filings with the U.S. Securities and Exchange Commission (the SEC), including the Company's most recent Annual Report on Form 20-F filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates.

| <u>Exhibit No.</u> | <u>Exhibit</u> |
|--------------------|--|
| 99.1 | Translation of notice to Federal Supervisory Agency for Financial Services |

Exhibit 99.1

The following notice has been submitted to the Federal Supervisory Agency for Financial Services (Bundesanstalt für Finanzdienstleistungsaufsicht) and published by LION bioscience AG:

Translation:

Dr. Anna Catarina von Bohlen und Halbach, Germany, has notified us pursuant to § 21 Paragraph 1, Sentence 1 of the Securities Trading Act (Wertpapierhandelsgesetz) that she no longer holds the threshold of 5% of the voting rights in LION bioscience AG. According to her, the amount of her voting shares is about 4.41%, which represents 878,888 votes, after the sale of 161,918 bearer shares.

Heidelberg, in February 2004

The Management Board

Edgar Filing: LION BIOSCIENCE AG - Form 6-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

LION bioscience Aktiengesellschaft

By: /s/ MARTIN HOLLENHORST

Martin Hollenhorst

Co-Chief Executive Officer and Chief Financial Officer

Dated: March 26, 2004